Stockscreener 앱 받기
4.41
7.56%
0.31
시간 외 거래:
4.42
0.010
+0.23%
전일 마감가:
$4.10
열려 있는:
$4.18
하루 거래량:
1.88M
Relative Volume:
1.38
시가총액:
$285.32M
수익:
$500
순이익/손실:
$-54.44M
주가수익비율:
-3.7828
EPS:
-1.1658
순현금흐름:
$-49.91M
1주 성능:
+12.50%
1개월 성능:
-14.53%
6개월 성능:
-19.82%
1년 성능:
+142.31%
1일 변동 폭
$4.16
$4.545
1주일 범위
$3.86
$4.545
52주 변동 폭
$2.06
$10.08
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.41 | 271.08M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Leerink Partners | Outperform |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
Immuneering names Andrew Gengos as CFO - MSN
Immuneering names Andrew Gengos as chief financial officer - Investing.com
Immuneering names Andrew Gengos as chief financial officer By Investing.com - Investing.com Canada
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026 - Minichart
Immuneering doses first patient in phase 3 pancreatic cancer trial - Investing.com
Immuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
Uprising in pancreatic space more than Revolution - BioWorld News
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Mizuho reiterates Immuneering stock rating after trial data update - Investing.com
Immuneering Corporation 8-K SEC Filing: Company Information, NASDAQ Listing, and Compliance Details (June 1, 2026) - Minichart
According to a document submitted to the U.S. Securities and Exchange Commission, as of April 24, 2026, biotechnology company Immuneering Corp observed a median overall survival of 17.3 months in the intent-to-treat population of its 320 mg dosage gro - Bitget
[8-K] Immuneering Corp Reports Material Event - Stock Titan
Immuneering stock maintained at Outperform by Oppenheimer on survival data - Investing.com South Africa
Immuneering reports median survival data from pancreatic trial - Investing.com
Immuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with Atebimetinib - Quiver Quantitative
Pancreatic cancer drug combo shows 17.3-month survival in trial - Stock Titan
Immuneering Corp stock (US45255L1089): IMRX trades around 5.36 USD ahead of key June data - AD HOC NEWS
Immuneering Corporation (IMRX) Slides 2.2% as Pressure Mounts Near Key SupportBreakout Stock Alerts - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentCFO Commentary Report - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower Loss Exceeds Expectations as Pipeline Progress ContinuesPre-Announcement Alert - newsline.com
MEK inhibitor delivers 17.3-month OS for pancreatic cancer - BioWorld News
IMRX Jumps As Immuneering Extends Cash Runway And Trial Pipeline - StocksToTrade
Immuneering reports 17.3-month survival in pancreatic cancer trial - Investing.com
Immuneering stock jumps on pancreatic cancer trial data By Investing.com - Investing.com Nigeria
Immuneering stock jumps on pancreatic cancer trial data - Investing.com
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy - The Manila Times
Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026 - Quiver Quantitative
Pancreatic cancer trial of Immuneering drug hits 17.3-month median survival - Stock Titan
Immuneering Corp stock (US45255L1089): clinical updates keep biotech investors watching - AD HOC NEWS
Immuneering Corporation (IMRX) Stock: Jumps +3.89%, Approaching $5.33 2026-05-20Diamond Pattern - The Legal Advocate
Can Revolution’s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes - BioSpace
Immuneering stock (US45255L1089): Insider buying puts the biotech back in focus - AD HOC NEWS
Immuneering Corporation Reports Q1 2026 Financial Results and Announces Positive Phase 2a Pancreatic Cancer Trial Data – Minichart - Minichart
Immuneering Corp Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Immuneering Hikes on Q1 Figures - Baystreet.ca
Immuneering to present pancreatic cancer trial data at ASCO - Investing.com
Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary - TradingView
Immuneering (IMRX) advances atebimetinib into MAPKeeper 301 Phase 3 - Stock Titan
Immuneering reports Q1 2026 net loss $13.5M, $198.6M cash runway into 2029 - TradingView
Pancreatic data and cash runway into 2029 at Immuneering (NASDAQ: IMRX) - Stock Titan
Pancreatic cancer patient gets 27 months progression-free on Immuneering drug - Stock Titan
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Immuneering Corp stock (US45255L1089): Q4 beat and 174% YTD surge - AD HOC NEWS
TradingKey - TradingKey
The one question every Immuneering Corporation (IMRX) investor should ask (Smart Money Flows) 2026-05-11Crowd Risk Alerts - newser.com
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors - TipRanks
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely - Yahoo Finance
Insider Buyers At Immuneering Sitting On US$361k Profit - Sahm
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immuneering Corp 주식 (IMRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brakewood Harold Eugene | Chief Business Officer |
Jan 16 '26 |
Buy |
4.76 |
5,250 |
24,990 |
11,050 |
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
| Feinberg Peter | Director |
Sep 30 '25 |
Buy |
7.03 |
7,500 |
52,730 |
149,266 |
2.60%
0.94%
자본화:
|
볼륨(24시간):